Company Overview

Tarsus Pharmaceuticals, Inc. is a U.S.-based commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for eye care, with an emphasis on diseases caused by parasites and inflammatory conditions with limited existing treatment options. The company operates within the ophthalmology and biopharmaceutical industries and targets conditions that are typically managed symptomatically rather than addressed at their root cause.

The company’s primary revenue driver is XDEMVY® (lotilaner ophthalmic solution) 0.25%, a prescription eye drop approved by the U.S. Food and Drug Administration for the treatment of Demodex blepharitis. Tarsus is positioned as the first company to bring an FDA-approved therapy specifically targeting the underlying parasitic cause of this condition. Founded in 2016, Tarsus Pharmaceuticals evolved from a clinical-stage biotechnology company into a commercial organization following FDA approval and launch of XDEMVY in 2023.

Business Operations

Tarsus operates as a single-reportable-segment biopharmaceutical company, generating revenue primarily through the commercialization of XDEMVY® in the United States. The company’s business model integrates internal research and development with outsourced manufacturing and a dedicated specialty sales force focused on eye care professionals, including ophthalmologists and optometrists.

Operations are primarily domestic, with commercialization activities concentrated in the U.S. market. Tarsus controls proprietary ophthalmic formulations based on lotilaner, an antiparasitic compound, and maintains intellectual property covering its use in ocular indications. As of publicly available filings, the company does not report material joint ventures; business activities are conducted directly through the parent company and wholly controlled operations.

Strategic Position & Investments

Tarsus’s strategic direction centers on maximizing the commercial adoption of XDEMVY® while advancing a pipeline of ophthalmic candidates that leverage its expertise in targeting parasitic and inflammatory eye diseases. Growth initiatives include expanding prescriber awareness, increasing patient access, and generating real-world clinical data to support broader utilization of its approved therapy.

The company continues to invest in research programs aimed at additional ocular indications, including conditions where Demodex mites or similar mechanisms may play a contributory role. Public disclosures confirm continued pipeline development, though specific clinical timelines beyond its lead program are limited; data inconclusive based on available public sources regarding late-stage assets outside XDEMVY.

Geographic Footprint

Tarsus Pharmaceuticals is headquartered in Irvine, California, and its commercial and corporate operations are primarily based in the United States. The company’s current product is approved only in the U.S., and revenue generation is concentrated in the domestic market.

While Tarsus has indicated interest in the long-term global potential of its ophthalmic assets, there is no verified disclosure of active international commercialization or regulatory approvals outside the United States as of the most recent public filings. Any future international expansion remains dependent on regulatory strategy and partnership decisions.

Leadership & Governance

Tarsus is led by an executive team with experience in ophthalmology, biotechnology commercialization, and clinical development. The leadership emphasizes a strategy focused on addressing underserved eye diseases through targeted, science-driven innovation and disciplined commercial execution.

Key executives include:

• Bobak Azamian, M.D., Ph.D. – President and Chief Executive Officer
• Laura Hanson – Chief Financial Officer

The company is publicly traded and governed by a board of directors responsible for overseeing corporate strategy, risk management, and compliance in alignment with U.S. public company standards.